Ocular Therapeutix, Inc. (OCUL)
Market Cap | 397.62M |
Revenue (ttm) | 51.49M |
Net Income (ttm) | -71.04M |
Shares Out | 77.51M |
EPS (ttm) | -0.97 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 366,192 |
Open | 5.35 |
Previous Close | 5.29 |
Day's Range | 5.12 - 5.40 |
52-Week Range | 2.57 - 6.53 |
Beta | 1.27 |
Analysts | Buy |
Price Target | 12.09 (+135.21%) |
Earnings Date | May 8, 2023 |
About OCUL
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing ... [Read more]
Financial Performance
In 2022, OCUL's revenue was $51.49 million, an increase of 18.32% compared to the previous year's $43.52 million. Losses were -$71.04 million, 984.1% more than in 2021.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for OCUL stock is "Buy." The 12-month stock price forecast is $12.09, which is an increase of 135.21% from the latest price.
News

What Makes Ocular Therapeutix (OCUL) a Good Fit for 'Trend Investing'
Ocular Therapeutix (OCUL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed thr...

Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 4% and 3.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix™ Provides Fourth Quarter and Year-End 2022 Results and Corporate Update
Presented Positive 10-month Interim Data from the U.S.-based Phase 1 Clinical Trial of OTX-TKI (axitinib intravitreal implant) for the Treatment of Wet AMD at the Angiogenesis, Exudation, and Degenera...

Ocular Therapeutix (OCUL) Moves 35.1% Higher: Will This Strength Last?
Ocular Therapeutix (OCUL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price i...

Ocular Therapeutix™ Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD
All OTX-TKI treated subjects who were rescue-free at the Month 7 interim analysis remained rescue-free, extending the 73% rescue-free rate up to Month 10

Ocular Therapeutix™ Provides 2022 Year End Corporate Update and Reviews Expected 2023 Milestones
Dextenza® Net Product Revenue in the Fourth Quarter of 2022 is Estimated to be $13.6 million, Growing Approximately 14% Over Previous Quarter and Approximately 11% Over Same Quarter of Prior Year

Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences
BEDFORD, Mass.

Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates (Revised)
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -30.43% and 18.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock...

Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -34.78% and 18.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock...

Ocular Therapeutix™ Reports Third Quarter 2022 Financial Results and Business Update
BEDFORD, Mass--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therap...

Ocular Therapeutix™ To Report Third Quarter 2022 Financial Results
BEDFORD, Mass.

Ocular Therapeutix (OCUL) Soars 24.2%: Is Further Upside Left in the Stock?
Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the nea...

Ocular (OCUL) Announces Positive Data on Wet AMD Candidate
Ocular (OCUL) interim seven-month data on OTX-TKI from a phase I study for treating wet age-related macular degeneration (wet AMD) shows a favorable safety profile, and stable and sustained visual acu...

Ocular Therapeutix™ Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD
BEDFORD, Mass--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therap...

Ocular Therapeutix™ To Present Data at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...

Ocular Therapeutix™ to Present at the H.C. Wainwright 24th Annual Global Investment Conference
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...

Ocular Therapeutix™ to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...

Ocular Therapeutix (OCUL) Reports Q2 Loss, Lags Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -21.74% and 11.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix™ Reports Second Quarter 2022 Financial Results and Business Update
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...

Ocular Therapeutix™ To Report Second Quarter 2022 Financial Results
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...

Aurion Biotech Appoints Dr. Michael Goldstein as President and Chief Medical Officer
SEATTLE, BOSTON & TOKYO--(BUSINESS WIRE)--Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has appointed Mic...

Ocular Therapeutix™ Announces Organizational Changes to Support Development for Retinal Diseases
BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases...

Ocular Therapeutix™ to Present at the Jefferies Healthcare Conference
BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases...

Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 12% and 12.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update
BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases...